Long-term benefit of nivolumab, ipilimumab, and pembrolizumab: 10-year survival data

The 10-year follow-up of the landmark KEYNOTE-006 and CheckMate 067 trials confirmed durable survival benefits for advanced melanoma patients treated with checkpoint inhibitors. Pembrolizumab and nivolumab plus ipilimumab showed the highest 10-year overall survival rates, at 34% and 43%, respectively, significantly improving long-term outcomes.

In KEYNOTE-006 (NCT01866319), 10-year overall survival (OS) was 34% for participants in the pembrolizumab arm versus 23% for participants in the ipilimumab arm [1]. Corrected for other causes of mortality, melanoma-specific survival after 10 years was 45% and 31%, respectively.

In CheckMate 067 (NCT01844505), 10-year survival was 37% for participants in the nivolumab arm, 19% for participants in the ipilimumab arm, and 43% for participants in the nivolumab plus ipilimumab arm [2]. Melanoma-specific survival after 10 years was 44%, 23%, and 52%, respectively.

These results confirm that checkpoint inhibitors have transformed the long-term prognosis for patients with advanced melanoma.

1. Robert C, et al. Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Abstract LBA44, ESMO Congress 2024, 13–17 September, Barcelona, Spain.
2. Larkin J, et al. 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma.Abstract LBA43, ESMO Congress 2024, 13–17 September, Barcelona, Spain.

 

Copyright ©2024 Medicom Medical Publishers



Posted on 4 November 20244 November 2024